Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Chromeceptin
Cat. No.:
0225LY-0579
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Chromeceptin is an inhibitor of the IGF signaling pathway that works by suppressing the AKT/mTOR pathway and reducing the quantity of tumorspheres.
Synonym:
2-Amino-7-(dimethylamino)-4-[3-(trifluoromethyl)phenyl]-4H-chromene-3-carbonitrile; 331859-86-0; 2-Amino-3-cyano-7-dimethylamino-4-(3-trifluoromethylphenyl)-4H-chromene
CAS No.:
331859-86-0
Compound CID:
3113922
Formula:
C19H16F3N3O
Formula Weight:
359.35
Specification
Relative Density:
1.36 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Chromeceptin can be used in cardiogenesis research to study the regulation of IGF signaling and cardiomyocyte proliferation.
Library Information
Target:
mTOR; Akt; IGF-1R
Receptor:
mTOR; Akt; IGF-1R
Pathways:
Cytoskeletal signaling; Tyrosine kinase/adaptors; PI3K/Akt/mTOR signaling
Plate Number:
AOCL-8
Plate Location:
e3
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
90 mg/mL; 250.45 mM
